Represents the clinical development milestone payment received by the entity during the period.

No definition available.

Name:	depo_ClinicalDevelopmentMilestonePaymentReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the milestone payment received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_MilestonePaymentReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the milestone payments following FDA's Acceptance.

+ References

No definition available.

+ Details

Name:	depo_MilestonePaymentsFollowingFDAsAcceptance
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of milestone payments received.

+ References

No definition available.

+ Details

Name:	depo_NumberOfMilestonePaymentsReceived
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of products elected to developed by utilizing Acuform technology under the agreement.

+ References

No definition available.

+ Details

Name:	depo_NumberOfProductsElectedToDevelop
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of products to be developed by utilizing Acuform technology under the agreement.

+ References

No definition available.

+ Details

Name:	depo_NumberOfProductsToBeDeveloped
Namespace Prefix:	depo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the upfront agreement fee received by the entity for formulation work to be performed under the agreement during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeeForFormulationWorkReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront agreement fee received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeeReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront agreement fees and milestone payments received by the entity during the period.

+ References

No definition available.

+ Details

Name:	depo_UpfrontAgreementFeesAndMilestonesPaymentReceived
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25383-109308

+ Details

Name:	us-gaap_RecordedUnconditionalPurchaseObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_IronwoodPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_MallinckrodtIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_PatheonPuertoRicoIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_SalixPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=depo_ValeantPharmaceuticalsInternationalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) (USD $)	3 Months Ended	1 Months Ended			3 Months Ended		77 Months Ended	1 Months Ended		45 Months Ended	0 Months Ended	1 Months Ended
	Mar. 31, 2014	Jun. 30, 2014	Apr. 30, 2014	Nov. 30, 2008 item	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2015 item	Aug. 31, 2012	Mar. 31, 2014	Mar. 31, 2015 item	Oct. 01, 2014	Jul. 31, 2008	Jul. 31, 2005
License and collaborative arrangements
License and other revenue	$ 11,760,000us-gaap_LicenseAndServicesRevenue
Mallinckrodt, Inc.
License and collaborative arrangements
Milestone payment received		5,000,000	10,000,000
Upfront fee received							4,000,000
Number of products to be developed by utilizing Acuform technology				4
Upfront fee received for formulation work to be performed under the agreement							1,500,000
Milestone revenue recognized	10,000,000					5,000,000
Number of products elected to develop				2
Upfront fees and milestones payment received							27,500,000
Number of milestone payments received							4
Clinical development milestone payments							500,000
Milestone payments following FDA's Acceptance					10,000,000		5,000,000
Janssen Pharmaceuticals, Inc.
License and collaborative arrangements
Upfront fee received								10,000,000
Ironwood Pharmaceuticals, Inc.
License and collaborative arrangements
Upfront fee received										3,400,000
Milestone revenue recognized									1,000,000
Number of milestone payments received										3
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) \| Commercialization Agreement
License and collaborative arrangements
License and other revenue	400,000
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) \| Promotion Agreement
License and collaborative arrangements
License and other revenue											1,900,000
Upfront fee received												12,000,000
Valeant Pharmaceuticals International, Inc.
License and collaborative arrangements
License and other revenue	400,000
Upfront fee received													25,000,000
Valeant Pharmaceuticals International, Inc. \| 1000mg Glumetza
License and collaborative arrangements
License and other revenue											11,300,000
Patheon Puerto Rico, Inc.
License and collaborative arrangements
Non-cancelable purchase orders and minimum purchase obligations					$ 1,900,000		$ 1,900,000			$ 1,900,000